Table 2.

Pros and cons for Ven/HMA and ICT for older AML-fit patients.

	Pros	Cons
Ven/HMA	Possible outpatient management Low early mortality rate High response rate in either intermediate or unfavorable ELN risk categories	Undefined duration of therapy Complex antifungal prophylaxis Uncertainty on response evaluation Poor outcome at progression/relapse
ICT	Short-term therapy Fast bridge to allo-SCT	Low response rate in poor-risk patients Prolonged hospitalization Potentially high early mortality rate Toxicity restricting eligibility to allo-SCT